A new anti-diabetes drug from the 'gliptin' family soon to be launched in India promises to lower treatment cost for patients by 55-60%. The launch of 'Teneligliptin' by Mumbai-based Glenmark Pharma under Ziten and Zita Plus brands at an affordable price could prove to be a game-changer with savings of over Rs 10,000 per year for diabetics.
Subscribe to Tv9 Gujarati https://www.youtube.com/tv9gujarati
Follow us on Dailymotion at http://www.dailymotion.com/GujaratTV9
Like us on Facebook at https://www.facebook.com/tv9gujarati
Follow us on Twitter at https://twitter.com/Tv9Gujarat
Circle us on Google+ : https://plus.google.com/+tv9gujarat
Follow us on Pinterest at http://www.pinterest.com/tv9gujarati/pins/
